T-705 (Favipiravir) (Synonyms: Favilavir, Favipiravir) |
Catalog No.GC12350
One-Click Copy Product Info
|
T-705 (Favipiravir) is a broad-spectrum antiviral drug. T-705 exerts its antiviral effects by selectively inhibiting the RNA-dependent RNA polymerase (RdRp) of RNA viruses.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 259793-96-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
T-705 (Favipiravir) is a broad-spectrum antiviral drug[1]. T-705 exerts its antiviral effects by selectively inhibiting the RNA-dependent RNA polymerase (RdRp) of RNA viruses[2]. The catalytic domain of RdRp is highly conserved among a variety of RNA viruses, which endows T-705 with broad-spectrum antiviral activity[3], including against influenza virus, Ebola virus, Lassa virus, etc[4].
In vitro, treatment of H9c2 cardiomyoblasts and CCD-1079Sk skin fibroblasts with T-705 (200–400μM) for 24 hours significantly reduced intracellular ATP levels, inhibited the activity of mitochondrial electron transport chain complexes I and V, induced oxidative stress, and caused DNA damage [5]. Pre-treatment of IEC-6 intestinal epithelial cells with T-705 (1600mg/L) for 24 hours, followed by stimulation with TNF-α (50ng/mL) and IFN-γ (100ng/mL) for 48 hours, significantly suppressed inflammatory responses and decreased the expression of apoptosis- and necrosis-related proteins, thereby protecting intestinal epithelial cells from inflammatory damage[6].
In vivo, oral administration of T-705 (150mg/kg) twice daily to mice infected with Bourbon virus (BRBV-STL), starting on day 1 post-infection and continuing for 8 days, significantly reduced weight loss and increased survival rates in mice[7]. Oral treatment of mice infected with Mayaro virus (MAYV) with T-705 (300mg/kg) for 5 days significantly reduced viral RNA and infectious viral particles in the blood and tissues. T-705 also significantly decreased levels of liver disease markers aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) in the blood of MAYV-infected mice[8].
References:
[1] Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512.
[2] Korula P, Alexander H, John JS, et al. Favipiravir for treating COVID-19. Cochrane Database Syst Rev. 2024 Feb 5;2(2):CD015219.
[3] Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463.
[4] Smyk JM, Majewska A. Favipiravir in the Battle with Respiratory Viruses. Mini Rev Med Chem. 2022;22(17):2224-2236.
[5] Gunaydin-Akyildiz A, Aksoy N, Boran T, et al. Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells. Toxicol Lett. 2022 Dec 1;371:9-16.
[6] Ozgurbuz U, Kabadayi Ensarioglu H, et al. Favipiravir Protects Enterocytes From Cell Death After Inflammatory Storm. Cureus. 2023 Oct 21;15(10):e47417.
[7] Bricker TL, Shafiuddin M, Gounder AP, et al. Therapeutic efficacy of favipiravir against Bourbon virus in mice. PLoS Pathog. 2019 Jun 13;15(6):e1007790.
[8] Bengue M, Pintong AR, Liegeois F, et al. Favipiravir Inhibits Mayaro Virus Infection in Mice. Viruses. 2021 Nov 3;13(11):2213.
| Cell experiment [1]: | |
Cell lines | H9c2 cardiomyoblasts (rat cardiomyoblast cell line), CCD-1079Sk skin fibroblasts (human skin fibroblast cell line) |
Preparation Method | Cells were cultured in DMEM-F12 medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin at 37°C, 5% CO₂. Sub-culturing was done every 2–3 days. T-705 was applied at concentrations of 200μM and 400μM for 24 hours. |
Reaction Conditions | 200μM and 400μM; 24 hours |
Applications | T-705 significantly decreased intracellular ATP conten. T-705 also inhibited mitochondrial electron transport chain enzyme activities, particularly complex I and complex V. T-705 significantly increased oxidative stress. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Mice were intraperitoneally inoculated with 4x102pfu of BRBV-STL. T-705 (150mg/kg) was administered orally twice daily for 8 days, starting immediately after infection (pre-treatment), one day after infection (concurrent treatment), or three days after infection (post-treatment). |
Dosage form | 150mg/kg; oral gavage |
Applications | T-705 significantly reduced weight loss and increased survival rates in mice. |
References: | |
| Cas No. | 259793-96-9 | SDF | |
| Synonyms | Favilavir, Favipiravir | ||
| Chemical Name | 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide | ||
| Canonical SMILES | C1=C(N=C(C(=O)N1)C(=O)N)F | ||
| Formula | C5H4FN3O2 | M.Wt | 157.1 |
| Solubility | ≥ 6.2mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.3654 mL | 31.8269 mL | 63.6537 mL |
| 5 mM | 1.2731 mL | 6.3654 mL | 12.7307 mL |
| 10 mM | 636.5 μL | 3.1827 mL | 6.3654 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)